CTI BioPharma Corp. (NASDAQ: CTIC)

Engel Law PLLC is investigating whether fair value to CTI shareholders will result from the proposed acquisition of CTI BioPharma Corp. (NASDAQ: CTIC) by Swedish Orphan Biovitrum AB for $9.10 in cash for each CTI share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

CTI BioPharma Corp.

MM slash DD slash YYYY